222 related articles for article (PubMed ID: 28344814)
1. The role of chemotherapy and new targeted agents in the management of primary prostate cancer.
Kumar SS; Pacey S
J Clin Urol; 2016 Dec; 9(2 Suppl):30-37. PubMed ID: 28344814
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Primary radical therapy selection in high-risk non-metastatic prostate cancer.
Gnanapragasam VJ; Payne H; Syndikus I; Kynaston H; Johnstone T
Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):136-44. PubMed ID: 25441052
[TBL] [Abstract][Full Text] [Related]
4. Maximizing outcomes in genitourinary cancers across the treatment continuum.
Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
[TBL] [Abstract][Full Text] [Related]
5. Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.
Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
Adv Exp Med Biol; 2018; 1096():159-184. PubMed ID: 30324353
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer: emerging concepts. Part II.
Garnick MB; Fair WR
Ann Intern Med; 1996 Aug; 125(3):205-12. PubMed ID: 8686979
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
Oh WK
J Urol; 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. PubMed ID: 14610407
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant therapy for high-risk localized prostate cancer.
Yu EY; Oh WK
Curr Oncol Rep; 2003 May; 5(3):250-7. PubMed ID: 12667424
[TBL] [Abstract][Full Text] [Related]
9. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
10. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in the treatment of prostate cancer--is there a role?
Arianayagam M; Chang J; Rashid P
Aust Fam Physician; 2007 Sep; 36(9):737-9. PubMed ID: 17885709
[TBL] [Abstract][Full Text] [Related]
12. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
Lam ET; Glodé LM
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormonal therapy in carcinoma of the prostate.
Lee HH; Warde P; Jewett MA
BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.
Pietzak EJ; Eastham JA
Curr Urol Rep; 2016 May; 17(5):37. PubMed ID: 26968417
[TBL] [Abstract][Full Text] [Related]
18. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
van Meurs HS; Tajik P; Hof MH; Vergote I; Kenter GG; Mol BW; Buist MR; Bossuyt PM
Eur J Cancer; 2013 Oct; 49(15):3191-201. PubMed ID: 23850170
[TBL] [Abstract][Full Text] [Related]
19. Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
Zafeiriou Z; Jayaram A; Sharp A; de Bono JS
Drugs; 2016 Mar; 76(4):421-30. PubMed ID: 26873496
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
